Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
Nightingale Introduces Embrace Overbed Lighting
ATLANTA, Georgia, April 1 -- Nightingale, a part of Acuity Brands, issued the following news:
* * *
Nightingale Introduces Embrace Overbed Lighting
Rachael J Richards
Innovative, multifunction patient bed luminaire offers soothing yet functional illumination.
ATLANTA, March 31, 2025 - Nightingale, (www.nightingalelighting.com), an innovative, patient-centric lighting manufacturer for healthcare applications, today introduced its Embrace overbed luminaire, an innovative new form factor for multifunction patient lighting.
Embrace was created to provide the best possible solution to assist in
... Show Full Article
ATLANTA, Georgia, April 1 -- Nightingale, a part of Acuity Brands, issued the following news:
* * *
Nightingale Introduces Embrace Overbed Lighting
Rachael J Richards
Innovative, multifunction patient bed luminaire offers soothing yet functional illumination.
ATLANTA, March 31, 2025 - Nightingale, (www.nightingalelighting.com), an innovative, patient-centric lighting manufacturer for healthcare applications, today introduced its Embrace overbed luminaire, an innovative new form factor for multifunction patient lighting.
Embrace was created to provide the best possible solution to assist inrelieving patient stress due to overhead light. While traditional overbed lighting can become a direct and ever-present source of glare for the patient, Embrace pushes light outside of direct patient view, reducing glare, and contributing to a calmer and more humane setting for the patient. Applications include patient rooms, NICU, senior living, long-term care, and recovery rooms.
The multifunction patient bed luminaire offers ambient, exam, and night observation modes, with an optional dedicated reading light. Its curved overbed design situates itself in the patient's periphery instead of directly overhead, reducing glare and enveloping the patient in comfortable illumination. At the same time, it meets IES RP-29 suggested light levels for a patient room, ensuring that medical professionals have the necessary illumination to conduct examinations or procedures.
Embrace is a large-form surface-mount, which simplifies installation and provides greater design freedom in spaces with shallow plenums and crowded patient room ceilings. Suitable for installations in spaces with both grid ceilings and hard ceilings. Applicable for both new construction and renovation opportunities. It pairs with the SensorSwitch sealed wall switch and low voltage controller for plug-and-play intuitive control and can be integrated into the patient's pillow speaker control handset.
"With Embrace overbed, we were inspired by Florence Nightingale's refusal to accept the status quo," said Ben Grindle, Director of Product Development, Nightingale. "We've broken the linear mold, freed ourselves from the grid, and changed the shape of overbed lighting."
More information about Embrace overbed is available on their site at https://www.nightingalelighting.com/embrace-overbed.
About Nightingale:
Nightingale, a brand within the Acuity Brands Lighting (ABL) portfolio, is an innovative, patient-centric lighting manufacturer that focuses on the patient experience while balancing the functional needs of professional caregivers. Drawing on decades of lighting expertise, Nightingale solutions combine the best of design and illumination engineering to provide a more comforting and reassuring patient experience that emphasizes wellness.
Media Contact:
Jason Broadhurst
514-971-2514
jason.broadhurst@AcuityBrands.com
* * *
Original text here: https://insights.acuitybrands.com/news-releases/nightingale-introduces-embrace-overbed-lighting
[Category: BizConsumer Services]
IDC Predicts: By 2027, 45% of Asia/Pacific* Organizations Will Adopt Performance-Intensive Infrastructure to Accelerate Insights for AI and Analytics
NEEDHAM, Massachusetts, April 1 -- International Data Corp., a provider of market intelligence and advisory services, issued the following news release:
* * *
IDC Predicts: By 2027, 45% of Asia/Pacific/* Organizations Will Adopt Performance-Intensive Infrastructure to Accelerate Insights for AI and Analytics
SINGAPORE, 31 March 2025 - IDC predicts that, by 2027, 45% of A2000 organizations will adopt performance-intensive, software-driven, scale-out storage infrastructure and unified data management to accelerate insights for AI and analytics, according to the IDC FutureScape: Worldwide Generative
... Show Full Article
NEEDHAM, Massachusetts, April 1 -- International Data Corp., a provider of market intelligence and advisory services, issued the following news release:
* * *
IDC Predicts: By 2027, 45% of Asia/Pacific/* Organizations Will Adopt Performance-Intensive Infrastructure to Accelerate Insights for AI and Analytics
SINGAPORE, 31 March 2025 - IDC predicts that, by 2027, 45% of A2000 organizations will adopt performance-intensive, software-driven, scale-out storage infrastructure and unified data management to accelerate insights for AI and analytics, according to the IDC FutureScape: Worldwide GenerativeArtificial Intelligence 2025 Predictions -- APEJ Implications. This shift is driven by the need to manage vast and expanding datasets, ensure compliance with data sovereignty regulations, and overcome challenges like insufficient storage capacity and computational power for AI workloads.
Traditional storage systems struggle to keep pace with the scale and speed required for AI applications, prompting businesses to invest in scalable, flexible infrastructure that can handle unstructured data more efficiently. These software-defined and scale-out storage solutions offer the performance and scalability needed to process and analyze large volumes of data, enabling faster insights. Unified data management simplifies the integration and governance of diverse data sources, helping organizations unlock valuable insights more efficiently. This strategic focus on cloud modernization, sustainability, and distributed data strategies reflects a broader effort to align digital infrastructure with innovation goals, operational efficiencies, and regulatory requirements, allowing enterprises to fully leverage AI's transformative potential and stay competitive in an increasingly data-driven world.
"Agentic AI is bridging critical gaps in large-scale GenAI implementation, driving more tangible ROI. However, its full potential can only be realized if enterprises prioritize the development of event-driven architectures supported by a robust data foundation layer," says Deepika Giri, head of research, Big Data & AI at IDC Asia/Pacific (including Japan).
This study presents the top 10 predictions for GenAI initiatives through 2030. Each prediction is assessed based on its impact (a mix of cost and complexity to address) and time frame to the expected stated adoption level. This study also highlights IT impact and guidance for technology buyers for each prediction statement. The following are some of IDC's predictions representing the expected trends with potential impact on GenAI initiatives:
Unifying AI Governance: By 2026, 80% of APEJ organizations will be formalizing policies and oversight to address AI risks (e.g., ethical, brand, PII), aligning AI governance with strategic business goals.
GenAI POC to Production: In 2026, over one-third of APEJ organizations will be stuck in the experimental, point-solution phase of AI experimentation, requiring a shift of focus to enterprise use cases to deliver ROI.
GenAI for Cloud Security: By 2026, 40% of multicloud environments will leverage generative AI to streamline security and identity access management, reducing manual efforts by 50% across APEJ organizations.
Agentic Workflows: By 2026, 20% of frustrated knowledge workers with no development experience will take charge of transforming how they work by building their own agentic workflows, improving cycle times by 50%.
Each year, IDC releases its top technology predictions at worldwide, regional and country levels through its IDC FutureScape Reports and offers strategic and data-driven insights into what is ahead for the rapidly changing IT industry. These predictions have been used to shape the strategies and business objectives of technology leaders and business executives in the next 1-5 years. All the predictions stated here cover Asia/Pacific implications.
Catch an on-demand replay of IDC's 2025 Predictions presentations on AI Everywhere Playbook, Building an AI-Fueled Business, Unblocking AI Everywhere Blockers, and Mapping Growth Opportunities in an AI Everywhere Era by registering here.
Asia/Pacific Excluding Japan FutureScape Reports come with a complimentary report that provides specific recommendations for tech vendor sales and marketing leaders. Leverage IDC insights to better understand clients' priorities and enhance your storytelling and go-to market plans, access the IDC FutureScape: Worldwide GenAI 2025 Predictions - Asia/Pacific (Excluding Japan) Implications Positioning for Success - Opportunities for Tech Sales and Marketing Leaders market presentation here .
For more information about IDC FutureScape and other resources, please visit our regional FutureScape site. For sales inquiries on the IDC FutureScape framework and reports, please contact your IDC account manager or Tessa Rago at trago@idc.com. For media queries, please contact Michael de la Cruz at mdelacruz@idc.com or Miguel Carreon at mcarreon@idc.com.
*/ Asia/Pacific excluding Japan
About IDC FutureScape
IDC FutureScape reports are used to shape IT strategy and planning for the enterprise by providing a basic framework for evaluating IT initiatives in terms of their value to business strategy now and in the foreseeable future. IDC's FutureScape reports are comprised of a set of decision imperatives designed to identify a range of pending issues that CIOs and senior technology professionals will confront within a typical five-year business planning cycle.
About IDC
International Data Corporation (IDC) is the premier global provider of market intelligence, advisory services, and events for the information technology, telecommunications, and consumer technology markets. With more than 1,300 analysts worldwide, IDC offers global, regional, and local expertise on technology and industry opportunities and trends in over 110 countries. IDC's analysis and insight helps IT professionals, business executives, and the investment community to make fact-based technology decisions and to achieve their key business objectives. Founded in 1964, IDC is a wholly owned subsidiary of International Data Group (IDG), the world's leading tech media, data and marketing services company. To learn more about IDC, please visit www.idc.com. Follow IDC on Twitter at @IDCAP and LinkedIn. Subscribe to the IDC Blog for industry news and insights.
* * *
Original text here: https://www.idc.com/getdoc.jsp?containerId=prAP53286325
[Category: BizConsulting]
Fifth Third Small Business Catalyst Fund Awards Nearly $250,000 in Grants
CINCINNATI, Ohio, April 1 -- Fifth Third Bank issued the following news release:
* * *
Fifth Third Small Business Catalyst Fund Awards Nearly $250,000 in Grants
Inaugural grants will drive growth, broaden financial access for small businesses
CINCINNATI--Nearly 50 small businesses across the U.S. have been awarded $5,300 grants from the Fifth Third Small Business Catalyst Fund to broaden financial access and help drive future growth.
The Small Business Catalyst Fund empowers small businesses across Fifth Third's 11-state footprint to grow and create jobs in their communities and to build a
... Show Full Article
CINCINNATI, Ohio, April 1 -- Fifth Third Bank issued the following news release:
* * *
Fifth Third Small Business Catalyst Fund Awards Nearly $250,000 in Grants
Inaugural grants will drive growth, broaden financial access for small businesses
CINCINNATI--Nearly 50 small businesses across the U.S. have been awarded $5,300 grants from the Fifth Third Small Business Catalyst Fund to broaden financial access and help drive future growth.
The Small Business Catalyst Fund empowers small businesses across Fifth Third's 11-state footprint to grow and create jobs in their communities and to build amore equitable small business ecosystem. The grants are the first awards from the $7.85 million fund, which Fifth Third (NASDAQ: FITB) launched last fall in partnership with the Community Reinvestment Fund, USA (CRF).
"At Fifth Third, we are committed to increasing financial access and mobility in all of the communities we serve," said Kala Gibson, chief corporate responsibility officer for Fifth Third. "These inaugural grants from our Small Business Catalyst Fund will help locally-owned businesses across our footprint continue to grow and thrive. Small businesses form the foundation of our communities--and when they succeed, we all succeed."
The Small Business Catalyst Fund helps small and micro business owners obtain working capital when traditional lending is not an option by connecting them with potential capital options offered by trusted Community Development Financial Institutions (CDFIs). The program utilizes an innovative funding model that combines grants, micro loans and small business loans ranging from $5,000 to $750,000 to small businesses at various stages of maturity.
"Small businesses are essential to the success and vibrancy of communities across the country, yet many face significant challenges in securing the financing they need to grow," said Alexis Dishman, SVP & Chief Lending Officer for CRF. "In collaboration with Fifth Third Bank and our CDFI partners, CRF aims to expand financial opportunities and accelerate small business momentum through the creation of this innovative fund."
Grant recipients include The Country Meat Co. Marketplace in Cincinnati's Avondale neighborhood. Locally-owned and operated, The Country Meat Co. Marketplace became the Avondale community's first grocery store in 17 years when it opened in February.
"Fifth Third's support will help ease food related financial strain for members of the Avondale community as well as providing access to nutritional education and essential support," said co-owner Tennel Bryant.
The Small Business Catalyst Fund is funded by the Fifth Third Foundation, the Fifth Third Bank Community Development Corporation, and Rockefeller Philanthropy Advisors. CRF administers the fund's grants and small business loans and works alongside two regional CDFI microlending partners who focus on microloans and technical assistance: Ohio-based Economic & Community Development Institute (ECDI), and New York-based Ascendus.
Fifth Third has a proven track record of prioritizing financial access and community development through its Neighborhood Program, which creates and implements innovative place-based strategies to effect positive change in nine historically disinvested neighborhoods across the Bank's 11-state footprint. Fifth Third launched its neighborhood program in 2021, taking a place-based approach to community development where the Bank works with a lead partner organization and other local organizations to build ecosystems that drive real change through both financial and social investments. This collective ecosystem approach is focused on identifying solutions to key challenges in partnership with the community, with the goal of creating lasting, transformative change.
A full list of grant recipients and more information is available at www.SmallBusinessCatalystFund.com.
About the Fifth Third Foundation
Established in 1948, the Fifth Third Foundation was one of the first charitable foundations created by a financial institution. The Fifth Third Foundation supports worthy causes in the areas of health and human services, education, community development and the arts in the states where Fifth Third Bank operates.
About Fifth Third
Fifth Third is a bank that's as long on innovation as it is on history. Since 1858, we've been helping individuals, families, businesses and communities grow through smart financial services that improve lives. Our list of firsts is extensive, and it's one that continues to expand as we explore the intersection of tech-driven innovation, dedicated people and focused community impact. Fifth Third is one of the few U.S.-based banks to have been named among Ethisphere's World's Most Ethical Companies for several years. With a commitment to taking care of our customers, employees, communities and shareholders, our goal is not only to be the nation's highest performing regional bank, but to be the bank people most value and trust.
Fifth Third Bank, National Association is a federally chartered institution. Fifth Third Bancorp is the indirect parent company of Fifth Third Bank and its common stock is traded on the NASDAQ Global Select Market under the symbol "FITB." Investor information and press releases can be viewed at www.53.com. Deposit and credit products provided by Fifth Third Bank, National Association. Member FDIC.
About Community Reinvestment Fund, USA
Founded in 1988, Community Reinvestment Fund, USA (CRF) is a national non-profit organization with a mission to improve lives and strengthen communities through innovative financial solutions. CRF has injected more than $3.6 billion to stimulate job creation, economic development, and support community facilities. To learn more about CRF, visit www.crfusa.com.
* * *
Original text here: https://www.53.com/content/fifth-third/en/media-center/press-releases/2025/press-release-2025-03-31.html
[Category: BizFinancial Services]
Dolby Laboratories to Bring Dolby Cinema to India, Delivering a Premium Cinema Experience for Moviegoers
SAN FRANCISCO, California, April 1 -- Dolby Laboratories Inc. issued the following news release:
* * *
Dolby Laboratories to Bring Dolby Cinema to India, Delivering a Premium Cinema Experience for Moviegoers
LAS VEGAS, NV - March 31, 2025 - Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, announced that it will bring Dolby Cinema to India this year, marking a new era in premium cinema going experiences. City Pride in Pune, Allu Cineplex in Hyderabad, LA Cinema in Trichy, AMB Cinemas in Bengaluru, EVM Cinemas in Kochi, and G Cineplex in Ulikkal will be the
... Show Full Article
SAN FRANCISCO, California, April 1 -- Dolby Laboratories Inc. issued the following news release:
* * *
Dolby Laboratories to Bring Dolby Cinema to India, Delivering a Premium Cinema Experience for Moviegoers
LAS VEGAS, NV - March 31, 2025 - Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, announced that it will bring Dolby Cinema to India this year, marking a new era in premium cinema going experiences. City Pride in Pune, Allu Cineplex in Hyderabad, LA Cinema in Trichy, AMB Cinemas in Bengaluru, EVM Cinemas in Kochi, and G Cineplex in Ulikkal will be thefirst six exhibitors to open Dolby Cinema screens in India.
Dolby Cinema is set to transform how Indian audiences experience movies, offering them the opportunity to see and hear stories exactly as the filmmakers intended. This milestone not only sets a new benchmark for premium cinema experiences in India but also reinforces Dolby's commitment to elevating entertainment through innovation.
A premium cinema offering for moviegoers, Dolby Cinema combines state-of-the-art picture and sound. With Dolby Vision, the picture comes alive with amazing brightness and darker darks to offer a more lifelike sense of depth, rendering colours and detail unlike other movie screens. Studio grade Dolby Atmos transports guests inside the story with sound that flows all around them, including overhead. The sound in the cinema envelops viewers, making the story their reality. Dolby Cinema fully realizes the filmmaker's intent, putting moviegoers in the middle of the action. Combined with the Dolby Cinema design, all seats in the auditorium will be optimized to ensure every seat offers a "best seat in the house" experience for movie fans.
"The launch of Dolby Cinema in India is a pivotal moment for the country's entertainment sector," said Michael Archer, Vice President of Worldwide Cinema Sales and Partner Management, Dolby Laboratories. "Indian audiences are passionate about movies, and Dolby Cinema is the ultimate moviegoing experience. Since the opening of the first Dolby Cinema in 2014, Dolby Cinema has grown rapidly, encompassing 35 exhibitor partners and 14 countries. This announcement underscores our commitment to advancing cinematic storytelling, working closely with filmmakers, studios, and exhibitors to deliver extraordinary entertainment experiences."
A crucial step in bringing Dolby Cinema to India has been ensuring filmmakers have access to world-class post-production facility. In addition to 24 Dolby Atmos theatrical mix facilities in India, Dolby recently collaborated with Annapurna Studios in Hyderabad, to setup India's first Dolby Vision color grading facility for cinema, empowering Indian filmmakers with cutting-edge tools to enhance their visual storytelling.
About Dolby
Dolby Laboratories (NYSE: DLB) is based in San Francisco with offices around the globe. From movies and TV shows, to apps, music, sports, and gaming, Dolby transforms the science of sight and sound into spectacular experiences for billions of people worldwide. We partner with artists, storytellers, developers, and businesses to revolutionize entertainment and communications with Dolby Atmos, Dolby Vision, Dolby Cinema, and Dolby.io.
* * *
Original text here: https://news.dolby.com/en-WW/248478-dolby-laboratories-to-bring-dolby-cinema-to-india-delivering-a-premium-cinema-experience-for-moviegoers
[Category: BizEntertainment Industry]
BASF Establishes Global Production for Licity Anode Binders With Manufacturing Scale-Up in the United States
FLORHAM PARK, New Jersey, April 1 -- BASF Corp. issued the following news release:
* * *
BASF establishes global production for Licity anode binders with manufacturing scale-up in the United States
CHARLOTTE, NC, March 31, 2025 - BASF has expanded its manufacturing capabilities in the United States to include the production of Licity anode binders, aimed at supporting the rapidly evolving lithium-ion battery industry. Thanks to this new production capability, BASF now offers its Licity portfolio globally across all regions. BASF anticipates access to local supply of raw materials as well as
... Show Full Article
FLORHAM PARK, New Jersey, April 1 -- BASF Corp. issued the following news release:
* * *
BASF establishes global production for Licity anode binders with manufacturing scale-up in the United States
CHARLOTTE, NC, March 31, 2025 - BASF has expanded its manufacturing capabilities in the United States to include the production of Licity anode binders, aimed at supporting the rapidly evolving lithium-ion battery industry. Thanks to this new production capability, BASF now offers its Licity portfolio globally across all regions. BASF anticipates access to local supply of raw materials as well asglobal availability to remain top issues of concern for battery manufacturers and OEMS in the years ahead.
The Licity portfolio complements BASF's existing styrene-butadiene rubber (SBR) manufacturing footprint and enhances the company's longstanding technical expertise. BASF currently produces SBR binders for electric vehicle batteries at production sites in Jiangsu and Guangdong, China, as well as Ludwigshafen, Germany, and Hamina, Finland. With this latest expansion, BASF now adds manufacturing capabilities at Monaca, Pennsylvania, and Chattanooga, Tennessee.
Anode binders are small but important components that greatly impact battery performance and stability. BASF's water-based anode binders offer customers a sustainable option with high-quality and stable performance. The innovative BASF binders increase battery capacity, improve cycle stability and reduce battery charging time. Licity binders can be customized to meet various requirements, such as different technical focuses for pure graphite or silicon-containing anodes and in a variety of applications such as electric vehicles, energy storage systems, and consumer electronics.
BASF remains dedicated to providing North American customers with a portfolio that keeps pace with the rapidly evolving battery market.
"This is an important step for the North American battery industry," said Denise Hartmann, Senior Vice President of Dispersions & Resins Americas at BASF. "With the expansion of manufacturing capability for Licity anode binders in the United States, we are pleased to now support the growth of our customers in all regions of the world."
BASF's binders are specifically designed to overcome different limitations of lithium-ion batteries. They are waterborne binders with high colloidal stability that are very compatible with co-binders such as carboxymethyl cellulose (CMC). BASF's binders are characterized by excellent processability and superior coatings performance. Furthermore, they have outstanding mechanical and electrochemical properties.
About BASF
BASF Corporation, headquartered in Florham Park, New Jersey, is the North American affiliate of BASF SE, Ludwigshafen, Germany. BASF has approximately 16,000 employees in North America and had sales of $19.7 billion in 2024. For more information about BASF's North American operations, visit www.basf.com/us.
At BASF, we create chemistry for a sustainable future. Our ambition: We want to be the preferred chemical company to enable our customers' green transformation. We combine economic success with environmental protection and social responsibility. Around 112,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio comprises, as core businesses, the segments Chemicals, Materials, Industrial Solutions, and Nutrition & Care; our standalone businesses are bundled in the segments Surface Technologies and Agricultural Solutions. BASF generated sales of Euros65.3 billion in 2024. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the United States. Further information at www.basf.com.
* * *
Original text here: https://www.basf.com/us/en/media/news-releases/2025/03/P-US-25-12
[Category: Industrial Materials]
Allstate to Hold Q1 2025 Earnings Call May 1
NORTHBROOK, Illinois, April 1 -- Allstate, a property and casualty insurance company, issued the following news release:
* * *
Allstate to hold Q1 2025 earnings call May 1
NORTHBROOK, Ill., March 31, 2025 - The Allstate Corporation (NYSE: ALL) will host a conference call and webcast at 9 a.m. ET on Thursday, May 1, 2025, to discuss first-quarter 2025 financial results.
Allstate plans to file its results via a Form 8-K with the Securities and Exchange Commission (SEC) after 4:15 p.m. ET on Wednesday, April 30. The earnings release and investor supplement will be accessible shortly after filing
... Show Full Article
NORTHBROOK, Illinois, April 1 -- Allstate, a property and casualty insurance company, issued the following news release:
* * *
Allstate to hold Q1 2025 earnings call May 1
NORTHBROOK, Ill., March 31, 2025 - The Allstate Corporation (NYSE: ALL) will host a conference call and webcast at 9 a.m. ET on Thursday, May 1, 2025, to discuss first-quarter 2025 financial results.
Allstate plans to file its results via a Form 8-K with the Securities and Exchange Commission (SEC) after 4:15 p.m. ET on Wednesday, April 30. The earnings release and investor supplement will be accessible shortly after filingon the SEC's website (www.sec.gov) and Allstate's Investor Relations website (www.allstateinvestors.com).
Get Allstate financial news at www.allstateinvestors.com:
* View the Form 8-K, earnings release and investor supplement after filing.
* Join the live conference call and access the webcast replay, which will be posted shortly after the call concludes.
* Stay informed on financial news and material announcements by subscribing to Allstate's email alerts and RSS feeds, via the "Email Alerts" section on the site.
* Plan for future earnings calls and webcasts with preliminary dates and times.
About Allstate
The Allstate Corporation (NYSE: ALL) protects people from life's uncertainties with a circle of protection including cars, homes, electronic devices, benefits and identity theft. Products are available through a broad distribution network including Allstate agents, independent agents, major retailers, online and at the workplace. Allstate is widely known for the slogan "You're in Good Hands with Allstate." Financial information, including material announcements about The Allstate Corporation, is routinely posted on www.allstateinvestors.com.
* * *
Original text here: https://www.allstatenewsroom.com/news/allstate-to-hold-q1-2025-earnings-call-may-1/
[Category: BizInsurance]
AZD0780, a Novel Oral PCSK9 Inhibitor, Demonstrated Significant LDL Cholesterol (LDL-C) Reduction in PURSUIT Phase IIb Trial
WILMINGTON, Delaware, April 1 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care
Positive results from the PURSUIT Phase IIb trial for AstraZeneca's AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered
... Show Full Article
WILMINGTON, Delaware, April 1 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care
Positive results from the PURSUIT Phase IIb trial for AstraZeneca's AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administeredon top of standard-of-care statin therapy, as compared with placebo./1,2 AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite standard-of-care-lipid lowering therapies such as statins./1,2
These new data were presented today at the American College of Cardiology's (ACC) Annual Scientific Session & Expo in Chicago, Illinois, US and published simultaneously in JACC./1,2
At 12 weeks, AZD0780 30mg taken once-daily (when added to the standard-of-care statin therapy and administered without any fasting or food restrictions) led to a 50.7% reduction in LDL-C [95% CI: -59.0%, -42.4%, p<0.001]. Similar efficacy was observed regardless of whether trial participants received moderate- or high- intensity statin doses at baseline./1,2 In addition, AZD0780 30mg enabled 84% [95%CI: 74.4%-90.7%] of trial participants to meet their American Heart Association/American College of Cardiology guideline-recommended LDL-C target (<70 mg/dL), compared to 13% [95%CI: 7.2%-22.3%] of participants on background statin therapy alone./1,2
High LDL-C (70 mg/dL), a common type of dyslipidemia, is a key risk factor for atherosclerotic cardiovascular disease, including stroke and heart attack, and a significant public health concern./3 It is estimated that more than 70% of patients worldwide are currently not reaching guideline-recommended LDL-C targets./4-7
Dr. Michael J Koren, MD, CEO & Medical Director of Jacksonville Center for Clinical Research, Florida, US and PURSUIT Principal Investigator, said: "The PURSUIT Phase IIb trial demonstrates the potential of AZD0780 to provide a much-needed once-daily oral treatment option to deliver greater LDL cholesterol lowering on top of standard of care for millions of patients who remain at risk for serious cardiovascular events including premature death. These results are particularly important because the majority of patients with atherosclerotic disease today do not reach their LDL-C goals, despite availability of lipid-lowering therapies such as statins and injectable PCSK9 inhibitors."
Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: "These new data reflect AZD0780's ability to reduce LDL cholesterol in patients who need more options to manage their cholesterol and related risks when standard-of-care therapy is not enough. As a novel small molecule oral PCSK9 inhibitor that can be taken without fasting restrictions, AZD0780 has the potential to be a game changer that could offer LDL-C lowering with greater convenience for patients. Our work in dyslipidemia builds on our strong heritage in cardiovascular, renal and metabolic diseases where we are advancing novel therapies, alone or in combination with other molecules in our extensive portfolio, that could redefine treatment standards and patient outcomes."
AZD0780 was generally well tolerated, and adverse events (AEs) were comparable between the total AZD0780 treatment groups (38.2%) and placebo (32.6%)./1,2 The frequency of treatment discontinuations due to AEs was similar across AZD0780 (1.5%) and placebo (2.3%) groups./1,2
Data from PURSUIT are consistent with Phase I findings presented at
European Atherosclerosis Society (EAS) 2024./8
Notes
About Dyslipidemia
Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 4.4 million deaths worldwide annually.3 Despite current treatment options, the global burden of dyslipidemia is on the rise.4 More than 70% of patients with atherosclerotic cardiovascular disease (ASCVD) are still not achieving their LDL-C target, so there remains a vast unmet need among high-risk patients for more varied and effective treatment options./4-7
PURSUIT
PURSUIT is a Phase IIb, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy, safety and tolerability of AZD0780 in participants with dyslipidemia.2
PURSUIT assessed the efficacy, safety and tolerability of different doses of AZD0780 on LDL-C levels in patients with hypercholesterolemia. 428 patients on stable standard-of-care therapy with moderate- or high-intensity statins with or without ezetimibe with LDL-C levels 70 and <190 mg/dL were randomized (1:1:1:1:1) to receive AZD0780 (1 mg, 3 mg, 10 mg and 30 mg daily) or matching placebo. 426 patients started treatment./2
The primary objective of the study was to measure the effect of different doses of AZD0780 given once daily on LDL-C levels in patients with dyslipidemia receiving standard-of-care statins. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers was also investigated. The concentration of AZD0780 in blood at specific timepoints was measured, and the safety and tolerability of AZD0780 evaluated.
AZD0780
AZD0780 is an oral, small molecule PCSK9 inhibitor that is being developed by AstraZeneca as an innovative therapy for patients with elevated low-density lipoprotein cholesterol (LDL-C) levels which cannot be controlled by statins alone.2 PCSK9 is a well-known and validated target in LDL-C metabolism and inhibiting PCSK9 signalling has shown to be effective in reducing LDL-C levels in plasma.2 Lower LDL-C levels are associated with a reduction in the risk of long-term cardiovascular disease and major cardiovascular events./9 AstraZeneca is investigating the potential of AZD0780 as an oral small-molecule for use as a monotherapy or in fixed-dose combinations with other therapies in our extensive portfolio. Data from PURSUIT are consistent with Phase I findings for AZD0780 which demonstrated a statistically significant reduction of 51% in LDL-C levels on top of rosuvastatin treatment, with 80% total reduction from baseline, in treatment-naive participants with hypercholesterolemia./2
AstraZeneca in CVRM
Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca's main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way towards regenerative therapies. The Company's ambition is to improve and save the lives of millions of people, by better understanding the interconnections between CVRM diseases and targeting the mechanisms that drive them, so we can detect, diagnose and treat people earlier and more effectively.
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 125 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on social media @AstraZeneca.
Media Inquiries
Fiona Cookson
+1 212 814 3923
Chelsea Tressler
+1 302 885 2677
US Media Mailbox: usmediateam@astrazeneca.com
References
1./ Koren M, et al. Efficacy and safety of AZD0780, an oral small molecule PCSK9 inhibitor for treatment of hypercholesterolemia: Results from a Ph2b randomized placebo-controlled clinical trial. Presented at: American College of Cardiology Annual Scientific Session (ACC 2025); 2025 Mar 29-31; Chicago, IL.
2./ Koren MJ, et al. An oral, small molecule PCSK9 inhibitor for treatment of hypercholesterolemia: the PURSUIT randomized trial. J Am Coll Cardiol. 2025.
3./ World Heart Federation. Cholesterol. Available at: https://world-heart-federation.org/what-we-do/cholesterol/#:~:text=High%20blood%20cholesterol%20is%20one,or%207.8%25%20of%20all%20deaths [Last accessed: March 2025].
4./ Pirillo A, et al. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689-700.
5./ Cannon CP, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6:1060-1068.
6./ Ray KK, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624.
7./ Underberg J, et al. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgrad Med. 2022;134:752-762.
8./ Vega R, et al. AZD0780, the first oral small molecule PCSK9 inhibitor for the treatment of hypercholesterolemia: results from a randomized, single-blind, placebo-controlled phase 1 trial. Atherosclerosis. 2024;395:118514.
9./ Domanski MJ, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76(13):1507-1516.
JOURNAL: JACC https://www.jacc.org/doi/10.1016/j.jacc.2025.03.499
* * *
Original text here: https://www.astrazeneca-us.com/media/press-releases/2025/AZD0780-a-novel-oral-PCSK9-inhibitor-demonstrated-significant-LDL-cholesterol-LDL-C-reduction-in-PURSUIT-Phase-IIb-trial.html
[Category: BizPharmaceuticals]
